Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
- Resource Type
- Article
- Source
- The Lancet Respiratory Medicine; 20210101, Issue: Preprints
- Subject
- Language
- ISSN
- 22132600; 22132619